MCID: THY124
MIFTS: 39

Thyroid Gland Papillary Carcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Thyroid Gland Papillary Carcinoma

MalaCards integrated aliases for Thyroid Gland Papillary Carcinoma:

Name: Thyroid Gland Papillary Carcinoma 12 15
Papillary Carcinoma of the Thyroid Gland 12
Thyroid Cancer, Papillary 44

Classifications:



External Ids:

Disease Ontology 12 DOID:3969
MeSH 44 D000077273
NCIt 50 C4035
SNOMED-CT 67 255029007
UMLS 71 C0238463

Summaries for Thyroid Gland Papillary Carcinoma

Disease Ontology : 12 A differentiated thyroid gland carcinoma that is characterized by the small mushroom shape of the tumor which has a stem attached to the epithelial layer abd arises from the follicular cells of the thyroid gland.

MalaCards based summary : Thyroid Gland Papillary Carcinoma, also known as papillary carcinoma of the thyroid gland, is related to thyroid cancer, nonmedullary, 1 and differentiated thyroid carcinoma. An important gene associated with Thyroid Gland Papillary Carcinoma is BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase). The drugs Vemurafenib and Vorinostat have been mentioned in the context of this disorder. Affiliated tissues include thyroid, lymph node and breast.

Related Diseases for Thyroid Gland Papillary Carcinoma

Diseases related to Thyroid Gland Papillary Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Related Disease Score Top Affiliating Genes
1 thyroid cancer, nonmedullary, 1 31.3 GAS8-AS1 BRAF
2 differentiated thyroid carcinoma 30.6 GAS8-AS1 BRAF
3 thyroid carcinoma 30.2 GAS5 BRAF
4 multicentric papillary thyroid carcinoma 11.3
5 columnar cell variant papillary carcinoma 11.3
6 tall cell variant papillary carcinoma 11.3
7 goiter 10.5
8 thyroiditis 10.5
9 thyroid tumor 10.4
10 papillary carcinoma 10.3
11 thyroid carcinoma, familial medullary 10.3
12 hypoparathyroidism 10.3
13 thyroid gland medullary carcinoma 10.3
14 adenoma 10.3
15 pseudosarcomatous fibromatosis 10.3
16 fasciitis 10.3
17 myositis 10.1
18 pheochromocytoma 10.1
19 graves disease 1 10.1
20 oncocytoma 10.1
21 parathyroid carcinoma 10.1
22 multinodular goiter 10.1
23 fibroma 10.1
24 adrenal gland pheochromocytoma 10.1
25 adenoid cystic carcinoma 10.1
26 neutropenia 10.1
27 lymphadenitis 10.1
28 pericarditis 10.1
29 leiomyosarcoma 10.1
30 pulmonary tuberculosis 10.1
31 multiple endocrine neoplasia 10.1
32 tracheal stenosis 10.1
33 mixed connective tissue disease 10.1
34 systemic scleroderma 10.1
35 paraplegia 10.1
36 follicular adenoma 10.1
37 connective tissue disease 10.1
38 hyperthyroidism 10.1
39 neurofibroma 10.1
40 raynaud phenomenon 10.1
41 dysphagia 10.1
42 insulin-like growth factor i 10.0
43 hypothyroidism 10.0
44 thyroid gland disease 10.0
45 fibromatosis 10.0
46 bladder urothelial carcinoma 9.9 GAS5 CRNDE BRAF
47 retinitis pigmentosa 11 9.9 GAS5 CRNDE
48 papillary thyroid microcarcinoma 9.9
49 graves' disease 9.9
50 papillary adenocarcinoma 9.9

Graphical network of the top 20 diseases related to Thyroid Gland Papillary Carcinoma:



Diseases related to Thyroid Gland Papillary Carcinoma

Symptoms & Phenotypes for Thyroid Gland Papillary Carcinoma

Drugs & Therapeutics for Thyroid Gland Papillary Carcinoma

Drugs for Thyroid Gland Papillary Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 86)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vemurafenib Approved Phase 2 918504-65-1 23252090 42611257
2
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
3
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
4
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
5
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
6
Decitabine Approved, Investigational Phase 2 2353-33-5 451668
7
Crizotinib Approved Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
8
Entrectinib Approved, Investigational Phase 2 1108743-60-7 25141092
9
Ipilimumab Approved Phase 2 477202-00-9
10
Durvalumab Approved, Investigational Phase 2 1428935-60-7
11
Pembrolizumab Approved Phase 2 1374853-91-4
12
Iodine Approved, Investigational Phase 2 7553-56-2 807
13
Dabrafenib Approved, Investigational Phase 2 1195765-45-7 44462760 44516822
14
Trametinib Approved Phase 2 871700-17-3 11707110
15
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
16
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
17
Paclitaxel Approved, Vet_approved Phase 1, Phase 2 33069-62-4 36314
18
nivolumab Approved Phase 1, Phase 2 946414-94-4
19
Lenvatinib Approved, Investigational Phase 2 417716-92-8
20
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
21
Salmon calcitonin Approved, Investigational Phase 2 47931-85-1 16129616
22
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
23
Tremelimumab Investigational Phase 2 745013-59-6
24
Cadexomer iodine Experimental Phase 2 94820-09-4
25
Cediranib Investigational Phase 1, Phase 2 288383-20-0 9933475
26
Maleic acid Experimental Phase 1, Phase 2 110-16-7 444266
27
Calcitonin gene-related peptide Investigational Phase 2 83652-28-2
28 Mitogens Phase 2
29 Endothelial Growth Factors Phase 2
30 Histone Deacetylase Inhibitors Phase 2
31 Antibiotics, Antitubercular Phase 2
32 Anti-Bacterial Agents Phase 2
33 Antimetabolites Phase 2
34 Deoxyglucose Phase 2
35 Antiviral Agents Phase 2
36 Fluorides Phase 2
37 Liver Extracts Phase 2
38 Immunoglobulins Phase 2
39 Antibodies Phase 2
40 Antibodies, Monoclonal Phase 2
41 Cola Phase 1, Phase 2
42 Nutrients Phase 2
43 Trace Elements Phase 2
44 Anti-Infective Agents Phase 2
45 Anti-Infective Agents, Local Phase 2
46 Micronutrients Phase 2
47 Angiogenesis Inhibitors Phase 1, Phase 2
48 Immunologic Factors Phase 1, Phase 2
49 Antineoplastic Agents, Immunological Phase 1, Phase 2
50 Albumin-Bound Paclitaxel Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 91)
# Name Status NCT ID Phase Drugs
1 Decision Aid on Radioactive Iodine Treatment for Early Stage Papillary Thyroid Cancer (Randomized Controlled Trial) Completed NCT01083550 Phase 2, Phase 3
2 Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy Completed NCT01811212 Phase 2 Cabozantinib S-malate
3 An Open-Label, Multi-Center Phase II Study of the BRAF Inhibitor Vemurafenib in Patients With Metastatic or Unresectable Papillary Thyroid Cancer (PTC) Positive for the BRAF V600 Mutation and Resistant to Radioactive Iodine Completed NCT01286753 Phase 2 Vemurafenib
4 Phase II Study of Histone Deacetylase Inhibitor SAHA (Vorinostat) in Patients With Metastatic Thyroid Carcinoma Completed NCT00134043 Phase 2 vorinostat
5 A Phase II Study of Single Agent Depsipeptide (FK228) in Radioiodine (RAI)-Refractory Metastatic Non-medullary (Papillary, Follicular, and Hurthle Cell Variants) Thyroid Carcinoma Completed NCT00098813 Phase 2 romidepsin
6 A Phase II Trial of 17-Allylaminogeldanamycin (17AAG) in Advanced Medullary and Differentiated Thyroid Carcinoma Completed NCT00118248 Phase 2 tanespimycin
7 A Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma Completed NCT00104871 Phase 2 Bortezomib
8 Phase II Study of Decitabine in Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Radioiodine Completed NCT00085293 Phase 2 Decitabine
9 A Phase II Study of Single Agent Intravenous (IV) VEGF Trap in Patients With Poor Prognostic Recurrent and/or Metastatic Thyroid Cancer After RAI Therapy Completed NCT00729157 Phase 2
10 Thyroid Gland Removal With or Without Central Lymph Node Dissection in Treating Patients With Node Negative Thyroid Cancer Completed NCT02138214 Phase 2
11 Phase 2 Study of Selumetinib Hydrogen Sulfate in Iodine-131 Refractory Papillary Thyroid Carcinoma and Papillary Thyroid Carcinoma With Follicular Elements Completed NCT00559949 Phase 2 Selumetinib
12 Sutent Adjunctive Treatment of Differentiated Thyroid Cancer Completed NCT00668811 Phase 2 SU011248, Sutent
13 A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma Completed NCT01502410 Phase 2 sorafenib tosylate
14 Randomized Controlled Trial of Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in Patients With Low-risk Papillary Thyroid Cancer Completed NCT02408887 Phase 2
15 Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma Completed NCT00887107 Phase 2 Sorafenib (nexavar)
16 Phase II Study of Sunitinib in Iodine Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of Thyroid With Functional Imaging Correlation Completed NCT00519896 Phase 2 sunitinib malate
17 Phase II Study of PDR001 in Combination With MAPK Pathway Inhibitors in Patients With Radioiodine-Refractory Thyroid Cancer Recruiting NCT04544111 Phase 2 Trametinib;Dabrafenib;PDR001
18 A Phase 2 Study of Lenvatinib in Combination With Radioactive Iodine Therapy in Patients With Progressive RAI-Sensitive Differentiated Thyroid Cancer Recruiting NCT03506048 Phase 2 Lenvatinib
19 An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements Recruiting NCT02568267 Phase 2 Entrectinib
20 A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors Recruiting NCT03037385 Phase 1, Phase 2 pralsetinib (BLU-667)
21 Phase II Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab (CaboNivoIpi) in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR-Targeted Therapy Recruiting NCT03914300 Phase 2 Cabozantinib S-malate
22 A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma - The DUTHY Trial Recruiting NCT03753919 Phase 2 Durvalumab;Tremelimumab
23 A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors Recruiting NCT03899792 Phase 1, Phase 2 LOXO-292
24 Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study Active, not recruiting NCT02973997 Phase 2 Lenvatinib
25 A Phase 2 Study of Trametinib in Combination With Radioiodine (RAI) for RAS Mutant or RAS/RAF Wild-Type, RAI-Refractory Recurrent and/or Metastatic Thyroid Cancers Active, not recruiting NCT02152995 Phase 2 Trametinib
26 Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer Active, not recruiting NCT01208051 Phase 1, Phase 2 Cediranib;Cediranib Maleate;Lenalidomide
27 Phase II Trial of Sunitinib (SU11248) in Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers and Medullary Thyroid Cancers Active, not recruiting NCT00381641 Phase 2 Sunitinib;Sunitinib Malate
28 A Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma Active, not recruiting NCT01723202 Phase 2 dabrafenib;trametinib
29 Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination With Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers Active, not recruiting NCT02393690 Phase 2 Selumetinib
30 A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors Not yet recruiting NCT04731467 Phase 1, Phase 2 CM-24 and Nivolumab - Dose Escalation;CM-24 and Nivolumab - Expansion;CM-24, Nivolumab, and Nab paclitaxel - Expansion
31 Phase II Study of BAY 43-9006 in Patients With Metastatic Thyroid Carcinoma Terminated NCT00095693 Phase 2 sorafenib tosylate
32 Adaptive Tyrosine Kinase Inhibitor Therapy In Patients With Advanced Progressive Thyroid Cancer Terminated NCT03630120 Phase 2 Lenvatinib;Sorafenib;Cabozantinib;Vandetanib
33 A Phase 1 Drug-Drug Interaction Study of the Effects of XL184 on the Pharmacokinetics of a Single Oral Dose of Rosiglitazone in Subjects With Solid Tumors Completed NCT01100619 Phase 1 rosiglitazone;XL184
34 A Phase I Clinical Trial of Pazopanib in Combination With Escalating Doses of Radioactive 131I in Patients With Well-Differentiated Thyroid Carcinoma Refractory to Radioiodine, Despite Having Some Uptake Completed NCT01413113 Phase 1 pazopanib hydrochloride
35 A Phase I Trial of Herceptin and Interleukin-12 Completed NCT00004074 Phase 1
36 Detection of Thyroid Cancer and Central Lymph Node Metastases Using EMI-137 Enhanced Molecular Fluorescent Guided Imaging: a Multicentre Feasibility and Completed NCT03470259 Phase 1 IV adminstration of EMI-137
37 A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL281 Administered Orally to Subjects With Solid Tumors Completed NCT00451880 Phase 1 XL281;famotidine
38 A Phase I Study of Surgery Plus Intraoperative Photodynamic Therapy (PDT) in Patients With Resectable, Primary or Recurrent Head and Neck Cancer Completed NCT00470496 Phase 1 HPPH;photodynamic therapy
39 A Phase Ib Trial of Vemurafenib Plus Copanlisib to Enhance Radioiodine Avidity in Radioiodine-Refractory Thyroid Cancers Recruiting NCT04462471 Phase 1 Vemurafenib;Copanlisib
40 A Phase I Dose Escalation Trial to Determine if Imatinib Treatment Restores Sodium Iodide Symporter Function and Sensitivity to Radioiodine Treatment in Metastatic Thyroid Cancer Patients Recruiting NCT03469011 Phase 1 Imatinib Oral Tablet
41 From the Endoscope to the Robot, the Initial Experience of Robotic Thyroidectomy is Summarized Unknown status NCT03454477
42 Comparative Analysis Between A Bipolar Vessel Sealing and Cutting Device and the Tie and Suture Technique in Thyroidectomy: A Two Institution Randomized Clinical Trial Unknown status NCT02140476
43 Differences Protein Expression in Papillary Thyroid Carcinoma Unknown status NCT02814032
44 Association Of Prognosis And BRAF V600E Mutations In Papillary Thyroid Carcinoma Unknown status NCT01417442 Early Phase 1
45 Prospective Study on the Clinical Prognosis of Bilateral Central Lymph Node Dissection in the Patients With Unilateral Thyroid Papillary Carcinoma Unknown status NCT02648399
46 99mTechnetium-MIBI SPECT-CT for Pre-operative Evaluation of Cervical Lymph Node Metastasis in Papillary Thyroid Carcinoma; A Pilot Study Unknown status NCT00984191
47 Study on the Application of Convenient Foot-control Exhaust Method in Endoscopic Thyroidectomy Unknown status NCT03411187
48 The Risk Stratification of Papillary Thyroid Cancer With Atypia of Undetermined Significance(AUS)by Thyroid Fine-Needle Aspiration(FNA)Could be Assisted by Tumor Size for Precision Treatment Completed NCT04601298
49 Comparison Between the Axillary Bilateral-breast Approach (ABBA) and Bilateral Axillo-breast Approach (BABA) for Robotic Thyroidectomy Completed NCT02768753
50 The Effectiveness of Prophylactic Selective Lateral Neck Dissection in Papillary Thyroid Carcinoma Patients With Central Neck Metastasis Completed NCT01103557

Search NIH Clinical Center for Thyroid Gland Papillary Carcinoma

Cochrane evidence based reviews: thyroid cancer, papillary

Genetic Tests for Thyroid Gland Papillary Carcinoma

Anatomical Context for Thyroid Gland Papillary Carcinoma

MalaCards organs/tissues related to Thyroid Gland Papillary Carcinoma:

40
Thyroid, Lymph Node, Breast, Endothelial, Liver, Cortex, Colon

Publications for Thyroid Gland Papillary Carcinoma

Articles related to Thyroid Gland Papillary Carcinoma:

(show top 50) (show all 106)
# Title Authors PMID Year
1
Codon-specific translation reprogramming promotes resistance to targeted therapy. 6
29925953 2018
2
A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease. 6
28854169 2017
3
eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. 6
25079330 2014
4
Copper is required for oncogenic BRAF signalling and tumorigenesis. 6
24717435 2014
5
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. 6
24670642 2014
6
Germline mutations in oncogene-induced senescence pathways are associated with multiple sessile serrated adenomas. 6
24512911 2014
7
A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. 6
23685455 2013
8
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. 6
23302800 2013
9
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. 6
22281684 2012
10
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). 6
22113612 2011
11
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. 6
21107320 2010
12
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. 6
21107323 2010
13
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. 6
20823850 2010
14
Inhibition of mutated, activated BRAF in metastatic melanoma. 6
20818844 2010
15
BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. 6
18398503 2008
16
Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. 6
17785355 2007
17
BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. 6
17488796 2007
18
BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells. 6
17374713 2007
19
Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. 6
16772349 2006
20
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. 6
16174717 2005
21
High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. 6
15998781 2005
22
BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors. 6
16015629 2005
23
High incidence of thyroid cancer in long-standing goiters with thyroglobulin mutations. 6
16187918 2005
24
Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas. 6
15687339 2005
25
Mutations of BRAF and RAS are rare events in germ cell tumours. 6
15386408 2005
26
BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. 6
15342696 2004
27
Low frequency of BRAFT1796A mutations in childhood thyroid carcinomas. 6
15356022 2004
28
Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. 6
15181070 2004
29
BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. 6
15126572 2004
30
BRAF T1796A transversion mutation in various thyroid neoplasms. 6
15001635 2004
31
Mutational analysis of BRAF and K-ras in gastric cancers: absence of BRAF mutations in gastric cancers. 6
14513361 2003
32
BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. 6
14602780 2003
33
Exclusion of BRAFV599E as a melanoma susceptibility mutation. 6
12794760 2003
34
BRAF mutations in metastatic melanoma: a possible association with clinical outcome. 6
12960123 2003
35
High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. 6
12670889 2003
36
Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. 6
12644542 2003
37
Absence of exon 15 BRAF germline mutations in familial melanoma. 6
12619120 2003
38
High frequency of BRAF mutations in nevi. 6
12447372 2003
39
Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. 6
12198537 2002
40
Mutations of the BRAF gene in human cancer. 6
12068308 2002
41
Study of Essential and Toxic Metal Imbalances in the Scalp Hair of Thyroid Cancer Patients in Comparison with Healthy Donors. 61
32405688 2021
42
Histone Deacetylase Inhibitors and Papillary Thyroid Cancer. 61
33308111 2020
43
Leukocyte immunoglobulin-like receptor subfamily B member 1 potentially acts as a diagnostic and prognostic target in certain subtypes of adenocarcinoma. 61
32534335 2020
44
Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors. 61
32182156 2020
45
Papillary carcinoma in correlation to thyroidal duct cyst: A case series. 61
32042395 2020
46
The features of contrast enhanced ultrasound and BRAF V600E in papillary thyroid carcinoma. 61
32030223 2019
47
Low prevalence of symptomatic thyroid diseases and thyroid cancers in HIV-infected patients. 61
31857648 2019
48
Thyroid disease and cancer in kidney transplantation: a single-center analysis. 61
31074392 2019
49
Unusual Metastases in Papillary Microcarcinoma of Thyroid. 61
30713376 2019
50
[Treatment of Brain Metastases from Papillary Thyroid Carcinomas:Five Surgical Cases in Our Hospital and a Literature Review]. 61
30458434 2018

Variations for Thyroid Gland Papillary Carcinoma

ClinVar genetic disease variations for Thyroid Gland Papillary Carcinoma:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 BRAF NM_001374258.1(BRAF):c.1919T>A (p.Val640Glu) SNV Pathogenic 13961 rs113488022 7:140453136-140453136 7:140753336-140753336
2 LIG4 NM_206937.2(LIG4):c.1673A>C (p.Gln558Pro) SNV Likely pathogenic 620632 rs751409106 13:108861944-108861944 13:108209596-108209596
3 PALB2 NM_024675.3(PALB2):c.2147A>G (p.Asn716Ser) SNV Uncertain significance 232654 rs148335539 16:23641328-23641328 16:23630007-23630007
4 RUNX1 NM_001754.5(RUNX1):c.749G>A SNV Uncertain significance 239055 rs771614642 21:36206763-36206763 21:34834466-34834466

Cosmic variations for Thyroid Gland Papillary Carcinoma:

9 (show top 50) (show all 3512)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM84512724 ZNF276 thyroid,NS,carcinoma,papillary carcinoma c.*458A>G p.? 16:89738704-89738704 12
2 COSM149314757 ZFHX3 thyroid,NS,carcinoma,papillary carcinoma c.5539C>T p.Q1847* 16:72797143-72797143 12
3 COSM102040487 ZFHX3 thyroid,NS,carcinoma,papillary carcinoma c.2797C>T p.Q933* 16:72797143-72797143 12
4 COSM87290227 ZFHX3 thyroid,NS,carcinoma,papillary carcinoma c.5539C>T p.Q1847* 16:72797143-72797143 12
5 COSM89410732 ZBTB2 thyroid,NS,carcinoma,papillary carcinoma c.1012C>G p.P338A 6:151366054-151366054 12
6 COSM104240656 XPO1 thyroid,NS,carcinoma,papillary carcinoma c.1801C>G p.Q601E 2:61492121-61492121 12
7 COSM101976985 XPO1 thyroid,NS,carcinoma,papillary carcinoma c.994G>T p.E332* 2:61495508-61495508 12
8 COSM104887851 XPO1 thyroid,NS,carcinoma,papillary carcinoma c.1801C>G p.Q601E 2:61492121-61492121 12
9 COSM104882823 XPO1 thyroid,NS,carcinoma,papillary carcinoma c.994G>T p.E332* 2:61495508-61495508 12
10 COSM101980763 XPO1 thyroid,NS,carcinoma,papillary carcinoma c.1801C>G p.Q601E 2:61492121-61492121 12
11 COSM104236287 XPO1 thyroid,NS,carcinoma,papillary carcinoma c.994G>T p.E332* 2:61495508-61495508 12
12 COSM100784195 WT1 thyroid,NS,carcinoma,papillary carcinoma c.62C>G p.S21W 11:32428568-32428568 12
13 COSM149742603 WT1 thyroid,NS,carcinoma,papillary carcinoma c.698C>G p.S233W 11:32428568-32428568 12
14 COSM113487425 WT1 thyroid,NS,carcinoma,papillary carcinoma c.698C>G p.S233W 11:32428568-32428568 12
15 COSM130521627 WT1 thyroid,NS,carcinoma,papillary carcinoma c.62C>G p.S21W 11:32428568-32428568 12
16 COSM148596343 WT1 thyroid,NS,carcinoma,papillary carcinoma c.698C>G p.S233W 11:32428568-32428568 12
17 COSM111541510 WT1 thyroid,NS,carcinoma,papillary carcinoma c.698C>G p.S233W 11:32428568-32428568 12
18 COSM91385851 WT1 thyroid,NS,carcinoma,papillary carcinoma c.698C>G p.S233W 11:32428568-32428568 12
19 COSM147428865 WT1 thyroid,NS,carcinoma,papillary carcinoma c.698C>G p.S233W 11:32428568-32428568 12
20 COSM108961796 VTCN1 thyroid,NS,carcinoma,papillary carcinoma c.*223C>G p.? 1:117156620-117156620 12
21 COSM95875457 VTCN1 thyroid,NS,carcinoma,papillary carcinoma c.408C>G p.I136M 1:117156620-117156620 12
22 COSM131777043 VTCN1 thyroid,NS,carcinoma,papillary carcinoma c.114C>G p.I38M 1:117156620-117156620 12
23 COSM96873846 VTCN1 thyroid,NS,carcinoma,papillary carcinoma c.399C>G p.I133M 1:117156620-117156620 12
24 COSM91950419 VTCN1 thyroid,NS,carcinoma,papillary carcinoma c.98-3251C>G p.? 1:117156620-117156620 12
25 COSM90653017 VHL thyroid,NS,carcinoma,papillary carcinoma c.241C>T p.P81S 3:10142088-10142088 12
26 COSM88292485 VHL thyroid,NS,carcinoma,papillary carcinoma c.241C>T p.P81S 3:10142088-10142088 12
27 COSM135219954 TUBGCP4 thyroid,NS,carcinoma,papillary carcinoma c.*3803C>A p.? 15:43409017-43409017 12
28 COSM85466701 TSHR thyroid,NS,carcinoma,papillary carcinoma c.1897G>T p.D633Y 14:81143955-81143955 12
29 COSM85465336 TSHR thyroid,NS,carcinoma,papillary carcinoma c.1867G>T p.A623S 14:81143925-81143925 12
30 COSM131082360 TSHR thyroid,NS,carcinoma,papillary carcinoma c.1358T>C p.M453T 14:81143416-81143416 12
31 COSM131082578 TSHR thyroid,NS,carcinoma,papillary carcinoma c.1867G>T p.A623S 14:81143925-81143925 12
32 COSM136098316 TSHR thyroid,NS,carcinoma,papillary carcinoma c.572C>T p.S191L 14:81096665-81096665 12
33 COSM131089095 TSHR thyroid,NS,carcinoma,papillary carcinoma c.572C>T p.S191L 14:81096665-81096665 12
34 COSM133033568 TSHR thyroid,NS,carcinoma,papillary carcinoma c.572C>T p.S191L 14:81096665-81096665 12
35 COSM85465141 TSHR thyroid,NS,carcinoma,papillary carcinoma c.1358T>C p.M453T 14:81143416-81143416 12
36 COSM131082573 TSHR thyroid,NS,carcinoma,papillary carcinoma c.1868C>T p.A623V 14:81143926-81143926 12
37 COSM85471850 TSHR thyroid,NS,carcinoma,papillary carcinoma c.572C>T p.S191L 14:81096665-81096665 12
38 COSM131083920 TSHR thyroid,NS,carcinoma,papillary carcinoma c.1897G>T p.D633Y 14:81143955-81143955 12
39 COSM85469945 TSHR thyroid,NS,carcinoma,papillary carcinoma c.1915C>T p.P639S 14:81143973-81143973 12
40 COSM90554251 TSHR thyroid,NS,carcinoma,papillary carcinoma c.572C>T p.S191L 14:81096665-81096665 12
41 COSM131087323 TSHR thyroid,NS,carcinoma,papillary carcinoma c.1915C>T p.P639S 14:81143973-81143973 12
42 COSM85465330 TSHR thyroid,NS,carcinoma,papillary carcinoma c.1868C>T p.A623V 14:81143926-81143926 12
43 COSM151513167 TSC2 thyroid,NS,carcinoma,papillary carcinoma c.4364A>T p.D1455V 16:2084655-2084655 12
44 COSM136636431 TSC2 thyroid,NS,carcinoma,papillary carcinoma c.4592G>A p.C1531Y 16:2086290-2086290 12
45 COSM151513976 TSC2 thyroid,NS,carcinoma,papillary carcinoma c.4399G>C p.E1467Q 16:2084690-2084690 12
46 COSM147715293 TSC2 thyroid,NS,carcinoma,papillary carcinoma c.4631G>A p.C1544Y 16:2086290-2086290 12
47 COSM110104598 TSC2 thyroid,NS,carcinoma,papillary carcinoma c.4159G>C p.E1387Q 16:2084690-2084690 12
48 COSM148998275 TSC2 thyroid,NS,carcinoma,papillary carcinoma c.4562G>A p.C1521Y 16:2086290-2086290 12
49 COSM136618348 TSC2 thyroid,NS,carcinoma,papillary carcinoma c.4300G>C p.E1434Q 16:2084690-2084690 12
50 COSM151747459 TSC2 thyroid,NS,carcinoma,papillary carcinoma c.4304A>T p.D1435V 16:2084655-2084655 12

Expression for Thyroid Gland Papillary Carcinoma

Search GEO for disease gene expression data for Thyroid Gland Papillary Carcinoma.

Pathways for Thyroid Gland Papillary Carcinoma

GO Terms for Thyroid Gland Papillary Carcinoma

Sources for Thyroid Gland Papillary Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....